Targeting Trop-2 in solid tumors: future prospects

Saif Zaman, Hassan Jadid, Aaron C Denson, Jhanelle E Gray, Saif Zaman, Hassan Jadid, Aaron C Denson, Jhanelle E Gray

Abstract

Trop-2 is a transmembrane glycoprotein that is upregulated in all cancer types independent of baseline levels of Trop-2 expression. Trop-2 is an ideal candidate for targeted therapeutics due to it being a transmembrane protein with an extracellular domain overexpressed on a wide variety of tumors as well as its upregulated expression relative to normal cells. As a result, several Trop-2-targeted therapeutics have recently been developed for clinical use, such as anti-Trop-2 antibodies and Trop-2-targeted antibody-drug conjugates (ADC). Subsequently, multiple early-phase clinical trials have demonstrated safety and clinical benefit of Trop-2-based ADCs across multiple tumor types. This includes clinical benefit and tolerability in tumor types with limited treatment options, such as triple-negative breast cancer, platinum-resistant urothelial cancer, and small-cell lung cancer. In this review, we elaborate on all clinical trials involving Trop-2.

Keywords: Trop-2; antibody–drug conjugates; oncotargets; targeted therapy; trophoblast antigen 2.

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

    1. Ripani E, Sacchetti A, Corda D, Alberti S. Human Trop-2 is a tumor-associated calcium signal transducer. Int J Cancer. 1998;76(5):671–676.
    1. Guerra E, Trerotola M, Aloisi AL, et al. The Trop-2 signalling network in cancer growth. Oncogene. 2013;32(12):1594–1600.
    1. Guan H, Guo Z, Liang W, et al. Trop2 enhances invasion of thyroid cancer by inducing MMP2 through ERK and JNK pathways. BMC Cancer. 2017;17(1):486.
    1. Stoyanova T, Goldstein AS, Cai H, et al. Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via b-catenin signaling. Genes Dev. 2012;26(20):2271–2285.
    1. El Sewedy T, Fornaro M, Alberti S. Cloning of the murine Trop2 gene: conservation of a PIP2-binding sequence in the cytoplasmic domain of Trop-2. Int J Cancer. 1998;75(2):324–330.
    1. Fong D, Moser P, Krammel C, et al. High expression of Trop2 correlates with poor prognosis in pancreatic cancer. Br J Cancer. 2008;99(8):1290–1295.
    1. Ning S, Guo S, Xie J, et al. Trop2 correlates with microvessel density and poor prognosis in hilar cholangiocarcinoma. J Gastrointest Surg. 2013;17(2):360–368.
    1. Liu T, Liu Y, Bao X, et al. Overexpression of Trop2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway. PLoS One. 2013;8(9):e75864.
    1. Zhao W, Zhu H, Zhang S, et al. Trop2 is overexpressed in gastric cancer and predicts poor prognosis. Oncotarget. 2016;7(5):6136–6145.
    1. Zeng P, Chen MB, Zhou LN, et al. Impact of Trop2 expression on prognosis in solid tumors: a systematic review and meta-analysis. Sci Rep. 2016;6:33658.
    1. Lipinski M, Parks DR, Rouse RV, Herzenberg LA. Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc Natl Acad Sci U S A. 1981;78(8):5147–5150.
    1. Alberti S, Miotti S, Stella M, et al. Biochemical characterization of Trop-2, a cell surface molecule expressed by human carcinomas: formal proof that the monoclonal antibodies T16 and MOv-16 recognize Trop-2. Hybridoma. 1992;11(5):539–545.
    1. Klein CE, Cordon-Cardo C, Soehnchen R, et al. Changes in cell surface glycoprotein expression during differentiation of human keratinocytes. J Invest Dermatol. 1987;89(5):500–506.
    1. Trerotola M, Cantanelli P, Guerra E, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene. 2013;32(2):222–233.
    1. Zhang L, Zhou W, Velculescu VE, et al. Gene expression profiles in normal and cancer cells. Science. 1997;276(5316):1268–1272.
    1. Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Gene Canc. 2015;6(3–4):84–105.
    1. Wang J, Zhang K, Grabowska D, et al. Loss of Trop2 promotes carcinogenesis and features of epithelial to mesenchymal transition in squamous cell carcinoma. Mol Canc Res. 2011;9(12):1686–1695.
    1. McDougall AR, Tolcos M, Hooper SB, Cole TJ, Wallace MJ. Trop2: from development to disease. Dev Dyn. 2015;244(2):99–109.
    1. Cubas R, Zhang S, Li M, Chen C, Yao Q. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer. 2010;9:253.
    1. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol. 2000;10(6):415–433.
    1. Zaman S, Chobrutskiy BI, Patel JS, et al. Mutant cytoskeletal and ECM peptides sensitive to the ST14 protease are associated with a worse outcome for glioblastoma multiforme. Biochem Biophys Res Commun. 2018;503(4):2218–2225.
    1. Zaman S, Chobrutskiy BI, Patel JS, et al. MMP7 sensitivity of mutant ECM proteins: an indicator of melanoma survival rates and T-cell infiltration. Clin Biochem. 2019;63:85–91.
    1. Wang D, Wang D, Wang N, Long Z, Ren X. Long non-coding RNA BANCR promotes endometrial cancer cell proliferation and invasion by regulating MMP2 and MMP1 via ERK/MAPK signaling pathway. Cell Physiol Biochem. 2016;40(3–4):644–656.
    1. Poudel B, Lee YM, Kim DK. DDR2 inhibition reduces migration and invasion of murine metastatic melanoma cells by suppressing MMP2/9 expression through ERK/NF-κB pathway. Acta Biochim Biophys Sin. 2015;47(4):292–298.
    1. Liu Y, Zhu P, Wang Y, et al. Antimetastatic therapies of the polysul-fide diallyl trisulfide against triple-negative breast cancer (TNBC) via suppressing MMP2/9 by blocking NF-κB and ERK/MAPK signaling pathways. PLoS One. 2015;10(4):e0123781.
    1. Li Z, Jiang X, Zhang W. Trop2 overexpression promotes proliferation and invasion of lung adenocarcinoma cells. Biochem Biophys Res Commun. 2016;470(1):197–204.
    1. Wu B, Yu C, Zhou B, et al. Overexpression of Trop2 promotes proliferation and invasion of ovarian cancer cells. Exp Ther Med. 2017;14(3):1947–1952.
    1. Zhao P, Zhang Z. TNF-a promotes colon cancer cell migration and invasion by upregulating Trop-2. Oncol Lett. 2018;15(3):3820–3827.
    1. Gao XY, Zhu YH, Zhang LX, Lu HY, Jiang AG. siRNA targeting of Trop2 suppresses the proliferation and invasion of lung adenocarcinoma H460 cells. Exp Ther Med. 2015;10(2):429–434.
    1. Trerotola M, Jernigan DL, Liu Q, et al. Trop-2 promotes prostate cancer metastasis by modulating b(1) integrin functions. Cancer Res. 2013;73(10):3155–3167.
    1. Trerotola M, Li J, Alberti S, Languino LR. Trop-2 inhibits prostate cancer cell adhesion to fibronectin through the b1 integrin-RACK1 axis. J Cell Physiol. 2012;227(11):3670–3677.
    1. Nakashima K, Shimada H, Ochiai T, et al. Serological identification of Trop2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Int J Cancer. 2004;112(6):1029–1035.
    1. Ohmachi T, Tanaka F, Mimori K, et al. Clinical significance of Trop2 expression in colorectal cancer. Clin Cancer Res. 2006;12(10):3057–3063.
    1. Wang J, Day R, Dong Y, Weintraub SJ, Michel L. Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther. 2008;7(2):280–285.
    1. Kong JS, Kim HJ, Kim MJ, et al. The significance of Trop2 expression in predicting BRAF mutations in papillary thyroid carcinoma. J Pathol Transl Med. 2018;52(1):14–20.
    1. Zhao W, Kuai X, Zhou X, et al. Trop2 is a potential biomarker for the promotion of EMT in human breast cancer. Oncol Rep. 2018;40(2):759–766.
    1. Gu QZ, Nijiati A, Gao X, et al. Trop2 promotes cell proliferation and migration in osteosarcoma through PI3K/AKT signaling. Mol Med Rep. 2018;18(2):1782–1788.
    1. Jordheim LP, Chettab K, Cros-Perrial E, Matera EL, Dumontet C. Unexpected growth-promoting effect of oxaliplatin in excision repair cross-complementation group 1 transfected human colon cancer cells. Pharmacology. 2018;102(3–4):161–168.
    1. Zhang L, Yang G, Zhang R, et al. Curcumin inhibits cell proliferation and motility via suppression of Trop2 in bladder cancer cells. Int J Oncol. 2018;53(2):515–526.
    1. Mangino G, Grazia Capri M, Barnaba V, Alberti S. Presentation of native Trop-2 tumor antigens to human cytotoxic T lymphocytes by engineered antigen-presenting cells. Int J Cancer. 2002;101(4):353–359.
    1. Lin H, Zhang H, Wang J, et al. A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo. Int J Cancer. 2014;134(5):1239–1249.
    1. Ikeda M, Yamaguchi M, Kato K, et al. Pr1E11, a novel anti-Trop-2 antibody isolated by adenovirus-based antibody screening, recognizes a unique epitope. Biochem Biophys Res Commun. 2015;458(4):877–882.
    1. Son S, Shin S, Rao NV, et al. Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy. Int J Biol Macromol. 2018;110:406–415.
    1. Strop P, Tran TT, Dorywalska M, et al. RN927C, a site-specific Trop-2 antibody-drug conjugate (ADC) with enhanced stability, is highly efficacious in preclinical solid tumor models. Mol Cancer Ther. 2016;15(11):2698–2708.
    1. Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) Oncotarget. 2015;6(26):22496–22512.
    1. Sharkey RM, McBride WJ, Cardillo TM, et al. Enhanced delivery of SN-38 to human tumor xenografts with an anti-Trop-2-SN-38 antibody conjugate (sacituzumab govitecan) Clin Cancer Res. 2015;21(22):5131–5138.
    1. Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Goldenberg DM. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011;17(10):3157–3169.
    1. Han C, Bellone S, Schwartz PE, et al. Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: a case report. Gynecol Oncol Rep. 2018;25:37–40.
    1. Cardillo TM, Sharkey RM, Rossi DL, et al. Synthetic lethality exploitation by an anti-Trop-2-SN-38 antibody-drug conjugate, IMMU-132, plus PARP inhibitors in BRCA1/2-wild-type triple-negative breast cancer. Clin Cancer Res. 2017;23(13):3405–3415.
    1. Chang CH, Wang Y, Zalath M, et al. Combining ABCG2 inhibitors with IMMU-132, an anti-Trop-2 antibody conjugate of SN-38, overcomes resistance to SN-38 in breast and gastric cancers. Mol Cancer Ther. 2016;15(8):1910–1919.
    1. Farivar TN, Najafipour R, Johari P. Nano – drug delivery of apoptosis activator 2 to AGS cells by liposomes conjugated with anti-Trop2 antibody. N Am J Med Sci. 2012;4(11):582–585.
    1. Liu D, Cardillo TM, Wang Y, et al. Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer. Mol Cancer. 2014;13:53.
    1. Bailly C, Cléry PF, Faivre-Chauvet A, et al. Immuno-PET for clinical theranostic approaches. Int J Mol Sci. 2016;18(1):57.
    1. Sharkey RM, van Rij CM, Karacay H, et al. A new Tri-Fab bispecific antibody for pretargeting Trop-2-expressing epithelial cancers. J Nucl Med. 2012;53(10):1625–1632.
    1. van Rij CM, Lütje S, Frielink C, et al. Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-Trop-2 X anti-HSG bispecific antibody. Eur J Nucl Med Mol Imaging. 2013;40(9):1377–1383.
    1. van Rij CM, Frielink C, Goldenberg DM, et al. Pretargeted immunoPET of prostate cancer with an anti-Trop-2 X anti-HSG bispecific antibody in mice with PC3 xenografts. Mol Imaging Biol. 2015;17(1):94–101.
    1. van Rij CM, Frielink C, Goldenberg DM, et al. Pretargeted radioimmunotherapy of prostate cancer with an anti-Trop-2×anti-HSG bispecific antibody and a (177)Lu-labeled peptide. Canc Biother Radiopharm. 2014;29(8):323–329.
    1. Campos MP, Konecny GE. The target invites a foe: antibody-drug conjugates in gynecologic oncology. Curr Opin Obstet Gynecol. 2018;30(1):44–50.
    1. King GT, Eaton KD, Beagle BR, et al. A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors. Invest New Drugs. 2018;36(5):836–847.
    1. Cardillo TM, Govindan SV, Sharkey RM, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers. Bioconjug Chem. 2015;26(5):919–931.
    1. Starodub AN, Ocean AJ, Shah MA, et al. First-in-human trial of a novel anti-Trop-2 Antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res. 2015;21(17):3870–3878.
    1. Bardia A, Mayer IA, Diamond JR, et al. Efficacy and safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J Clin Oncol. 2017;35(19):2141–2148.
    1. Ambrogi F, Fornili M, Boracchi P, et al. Trop-2 is a determinant of breast cancer survival. PLoS One. 2014;9(5):e96993.
    1. Faltas B, Goldenberg DM, Ocean AJ, et al. Sacituzumab govitecan, a novel antibody–drug conjugate, in patients with metastatic platinum-resistant urothelial carcinoma. Clin Genitourin Canc. 2016;14(1):e75–e79.
    1. Heist RS, Guarino MJ, Masters G, et al. Therapy of advanced non-small-cell lung cancer with an SN-38-anti-Trop-2 drug conjugate, sacituzumab govitecan. J Clin Oncol. 2017;35(24):2790–2797.
    1. Gray JE, Heist RS, Starodub AN, et al. Therapy of small cell lung cancer (SCLC) with a topoisomerase-I-inhibiting antibody-drug conjugate (ADC) targeting Trop-2, sacituzumab govitecan. Clin Cancer Res. 2017;23(19):5711–5719.
    1. Rudin CM, Pietanza MC, Bauer TM, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017;18(1):42–51.
    1. Janku F, Hong DS, Fu S, et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 2014;6(2):377–387.
    1. Troiani T, Vecchione L, Martinelli E, et al. Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. Br J Cancer. 2012;106(10):1648–1659.
    1. Guerra E, Trerotola M, Tripaldi R, et al. Trop-2 induces tumor growth through Akt and determines sensitivity to Akt inhibitors. Clin Cancer Res. 2016;22(16):4197–4205.
    1. Wang X, Long M, Dong K, et al. Chemotherapy agents-induced immunoresistance in lung cancer cells could be reversed by Trop-2 inhibition in vitro and in vivo by interaction with MAPK signaling pathway. Cancer Biol Ther. 2013;14(12):1123–1132.
    1. Mojica WD, Brandwein-Weber M, Korangy EA. A case of metastatic lobular carcinoma with overexpression of trop-2: implications for the consideration of novel therapeutics. Breast J. 2017;23(6):757–759.
    1. Govindan SV, Cardillo TM, Sharkey RM, et al. Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers. Mol Cancer Ther. 2013;12(6):968–978.
    1. Okajima D, Yasuda S, Yokouchi Y, et al. Preclinical efficacy studies of DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd. J Clin Oncol. 2008;36(Suppl 15) abstract e24206.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다